Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma
Autops. Case Rep
; 8(1): e2018005, Jan.-Mar. 2018. ilus
Article
en En
| LILACS
| ID: biblio-905466
Biblioteca responsable:
BR26.7
ABSTRACT
Chemotherapy is considered "state of the art" for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor activity.
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Compuestos Organoplatinos
/
Neoplasias Gástricas
/
Carcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tumores Neuroendocrinos
/
Fluorouracilo
Límite:
Humans
/
Male
Idioma:
En
Revista:
Autops. Case Rep
Asunto de la revista:
Anatomia
/
Patologia Cl¡nica
/
Patologia Legal
Año:
2018
Tipo del documento:
Article